Testing for the Hidden Defect: Diagnosis and Interpretation
At a Glance
Immunodeficiency 107 is usually diagnosed by matching severe or invasive Staphylococcus aureus infections with a pathogenic or likely pathogenic loss-of-function variant in one copy of OTULIN. Routine blood tests may be normal, and a VUS does not confirm the condition.
Diagnosing Immunodeficiency 107 (IMD107) can be a confusing journey because it does not show up on the standard tests doctors use to check the immune system. Finding out that your standard blood tests are normal, despite experiencing severe infections, is a common and validating step in this process. While most immune disorders involve low white blood cell counts or missing antibodies, IMD107 involves a vulnerability within the structure of your skin and lung cells [1][2].
The Genetic Investigation
Because blood work is typically unremarkable, a central way to diagnose IMD107 is through genetic testing correlated carefully with your clinical symptoms. A molecular diagnosis requires finding a specific type of change in the OTULIN gene [2].
The hallmark of IMD107 is a monoallelic loss-of-function variant. This means:
- Monoallelic (Heterozygous): You have one working copy and one altered copy of the gene [3].
- Loss-of-Function: The altered copy provides no useful instructions, leaving you with a reduced amount of OTULIN protein (this state is called haploinsufficiency) [2][3].
Common types of variants that cause this include nonsense mutations, frameshift mutations, or splice-site variants [2][4].
When Genetics Aren’t Enough: VUS and Functional Testing
Sometimes, a genetic test finds a change in the OTULIN gene, but the lab isn’t sure if it actually causes the disease. This is called a Variant of Unknown Significance (VUS) [2]. A VUS does not establish disease and should not drive predictive testing for family members or treatment decisions.
In specialized research settings, functional testing on a skin biopsy has been used to study variants by looking for markers like linear ubiquitin build-up, Caveolin-1 accumulation, and alpha-toxin sensitivity in dermal fibroblasts [1]. However, these are research-level, non-routine tests with uncertain clinical validation. A skin biopsy is an invasive procedure and should not be pursued casually to investigate wound healing; it may only be considered through an expert laboratory after genetics consultation [1][5].
A Discussion Checklist for Your Reports
When you review your genetic report with a specialist, ask whether the laboratory evaluated the following details:
- Gene Name: OTULIN.
- Zygosity: Heterozygous (only one copy affected).
- Variant Nomenclature: Includes DNA (c.) and protein (p.) notations.
- Classification: Is it definitively classified as Pathogenic or Likely Pathogenic, rather than a VUS?
- Mechanism: Is it understood to be a “loss-of-function” or “haploinsufficiency” mutation? [6].
- Methodology: Did the test include sequencing as well as deletion/duplication analysis (copy-number analysis)? [4].
The Importance of Family Testing
Because IMD107 is an autosomal dominant condition, each child of a person who is heterozygous for a confirmed pathogenic variant has a 50% chance of carrying the variant [2]. A sibling’s risk is only 50% if one of the parents carries the variant; if the mutation arose de novo (new in you), the sibling risk is usually much lower.
Because the condition is incompletely penetrant, a family member could have the same genetic variant but have no history of severe infections [1][3]. Meeting with a genetic counselor is essential. They can help explain parental testing, clarify transmission risks, and explicitly guide family members on the implications of cascade testing [3][6].
Common questions in this guide
What genetic result supports a diagnosis of IMD107?
Can routine immune blood tests be normal with IMD107?
What does a VUS in the OTULIN gene mean?
What should I look for in my OTULIN genetic report?
How is IMD107 inherited, and could a carrier have no symptoms?
Is a skin biopsy routinely used to diagnose IMD107?
Get notified when new evidence is published on immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (6)
- 1
Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin.
Spaan AN, Neehus AL, Laplantine E, et al.
Science (New York, N.Y.) 2022; (376(6599)):eabm6380 doi:10.1126/science.abm6380.
PMID: 35587511 - 2
Novel genotypes, phenotypes, and triggers in humans with OTULIN haploinsufficiency.
van der Linden TJ, Arts RJW, Biggs CM, et al.
Journal of human immunity 2025; (1(4)) doi:10.70962/jhi.20250018.
PMID: 41293556 - 3
OTULIN-related conditions: Report of a new case and review of the literature using GenIA.
Caballero-Oteyza A, Crisponi L, Peng XP, et al.
Clinical immunology (Orlando, Fla.) 2024; (265()):110292 doi:10.1016/j.clim.2024.110292.
PMID: 38914362 - 4
Clinical exome sequencing of 1000 families with complex immune phenotypes: Toward comprehensive genomic evaluations.
Similuk MN, Yan J, Ghosh R, et al.
The Journal of allergy and clinical immunology 2022; (150(4)):947-954 doi:10.1016/j.jaci.2022.06.009.
PMID: 35753512 - 5
Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease.
Zhou Q, Yu X, Demirkaya E, et al.
Proceedings of the National Academy of Sciences of the United States of America 2016; (113(36)):10127-32 doi:10.1073/pnas.1612594113.
PMID: 27559085 - 6
OTULIN-related conditions: Report of a new case and review of the literature using GenIA.
Caballero-Oteyza A, Crisponi L, Peng XP, et al.
Research square 2024; doi:10.21203/rs.3.rs-3950863/v2.
PMID: 38712244
This page is for informational purposes only and does not constitute medical advice. A clinical immunologist or genetics professional should interpret your OTULIN results and guide decisions about family testing.